The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06047080
Recruitment Status : Recruiting
First Posted : September 21, 2023
Last Update Posted : June 7, 2024
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 1, 2026
Estimated Study Completion Date : February 28, 2029